Syncom Formulations reports strong financial performance in Q2 FY24-25

Syncom Formulations (India), a smallcap pharmaceutical company, has recently announced its financial results for the quarter ending September 2024. The company has received a 'Hold' call from MarketsMOJO, indicating a neutral stance on its stock.

According to the financial report, Syncom Formulations has shown a very positive performance in the second quarter of FY24-25. The company's score has improved from 20 to 27 in the last three months, indicating a strong growth trend.

One of the key factors contributing to this growth is the company's net sales, which have been consistently increasing in the last five quarters. In the second quarter of FY24-25, the net sales were at Rs 102.31 crore, which is the highest in the last five quarters. This represents a growth of 41.2% over the average net sales of the previous four quarters.

The operating profit (PBDIT) has also shown a positive trend, with the highest recorded at Rs 12.16 crore in the second quarter. This has been a consistent growth trend in the last five quarters.

The profit before tax (PBT) has also seen a significant increase, with the highest recorded at Rs 10.70 crore in the second quarter. This represents a growth of 78.4% over the average PBT of the previous four quarters.

The company's profit after tax (PAT) has also shown a positive trend, with the highest recorded at Rs 11.11 crore in the second quarter. This represents a growth of 55.6% over the average PAT of the previous four quarters.

Overall, Syncom Formulations has shown a strong financial performance in the second quarter of FY24-25, with increasing sales and profitability. This has resulted in a higher earnings per share (EPS) of Rs 0.12, indicating a positive outlook for the company's shareholders.